Skip to content
Archive

News

The lastest news updates and press releases from Sarborg.

Press Release24 Feb 2026

Sarborg Expands AI Agentic Signature Platform Beyond Pharmaceuticals into Bacteria and Agrochemicals

The expansion of its proprietary AI Signature Agent platform into additional high-impact sectors, including bacteria and agrochemicals, following the successful deployment of its Pharmaceutical Signature Agent.

Press Release15 Dec 2025

Sarborg Develops and Curates “Sarborg 1,600” Gold Standard Disease Signature Database

The curation and development of its proprietary “Sarborg 1,600,” a gold standard database of approximately 1,600 structured disease signatures designed specifically for integration with the Company’s AI Signature Agent.

Press Release8 Dec 2025

Sarborg Signature Agent Completion

Sarborg announces the completion of development of its proprietary, AI Signature Agent, initially focused on matching drug and disease signatures within the pharmaceutical sector.

Press Release9 Sept 2025

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing

Press Release27 Aug 2025

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring